ASX:OSLOncosil Medical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oncosil Medical Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.12 +0.01 (+9.09 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.11Now: A$0.12▼A$0.1250-Day RangeA$0.12MA: A$0.12▼A$0.1252-Week RangeA$0.05Now: A$0.12▼A$0.22Volume2.17 million shsAverage VolumeN/AMarket Capitalization$81.24 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for cancer in Australia. Its lead product is OncoSil, a brachytherapy device comprising OncoSil Phosphorous-32 Microparticles and OncoSil Diluent, which implants a pre-determined dose of beta radiation emitting isotope directly into cancerous tissue for the treatment of pancreatic and liver cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Oncosil Medical. Previous Next 2.6 Community Rank Outperform VotesOncosil Medical has received 14 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOncosil Medical has received 13 “underperform” votes. (Add your “underperform” vote.)Community SentimentOncosil Medical has received 51.85% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Oncosil Medical and other stocks. Vote “Outperform” if you believe OSL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OSL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOncosil Medical does not currently pay a dividend.Dividend GrowthOncosil Medical does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncosil Medical insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Oncosil Medical are expected to grow in the coming year, from A($0.02) to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncosil Medical is -10.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncosil Medical is -10.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncosil Medical has a P/B Ratio of 10.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.65 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolASX:OSL Previous Symbol CUSIPN/A CIKN/A Webwww.oncosil.com.au Phone61 2 9223 3344Debt Debt-to-Equity Ratio3.15 Current Ratio7.31 Quick Ratio7.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.98 million Price / Sales27.27 Cash FlowA$0.01 per share Price / Cash Flow10.91 Book ValueA$0.01 per share Price / Book10.00Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares676,963,968Market Cap$81.24 million Next Earnings DateN/A OptionableNot Optionable Receive OSL News and Ratings via Email Sign-up to receive the latest news and ratings for OSL and its competitors with MarketBeat's FREE daily newsletter. Oncosil Medical (ASX:OSL) Frequently Asked Questions How has Oncosil Medical's stock been impacted by COVID-19 (Coronavirus)? Oncosil Medical's stock was trading at A$0.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OSL stock has increased by 9.1% and is now trading at A$0.12. View which stocks have been most impacted by Coronavirus. Has Oncosil Medical been receiving favorable news coverage? News headlines about OSL stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncosil Medical earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Oncosil Medical. Who are some of Oncosil Medical's key competitors? Some companies that are related to Oncosil Medical include Volpara Health Tech (VHT), Akumin (AKU), MaxCyte (MXCT), Exagen (XGN), Yourgene Health (YGEN), Senseonics (SENS), Palatin Technologies (PTN), Oncimmune (ONC), Lexagene (LXG), SQI Diagnostics (SQD), Genedrive (GDR), BARD1 Life Sciences (BD1), Sernova (SVA), GeneNews (GEN) and Imagion Biosys (IBX). View all competitors. What other stocks do shareholders of Oncosil Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncosil Medical investors own include WiseTech Global (WTC), Twitter (TWTR), Qube (QUB), Procter & Gamble (PG), Charter Hall Education Trust (CQE), Blackmores (BKL) and APA Group (APA). Who are Oncosil Medical's key executives? Oncosil Medical's management team includes the following people: Mr. Daniel Kenny B.Sc., CEO, MD & Exec. DirectorMr. Tom Milicevic B.Comm, FCPA, MBA MGSM, CFO & Company Sec. (Age 47)Mr. Michael Warrener, Global Sales & Marketing DirectorDr. Ashish Soman, Chief Medical OfficerDr. David C. James, Global Head of Manufacturing Operations What is Oncosil Medical's stock symbol? Oncosil Medical trades on the ASX under the ticker symbol "OSL." What is Oncosil Medical's stock price today? One share of OSL stock can currently be purchased for approximately A$0.12. How big of a company is Oncosil Medical? Oncosil Medical has a market capitalization of $81.24 million and generates $2.98 million in revenue each year. What is Oncosil Medical's official website? The official website for Oncosil Medical is www.oncosil.com.au. How can I contact Oncosil Medical? The company can be reached via phone at 61 2 9223 3344. This page was last updated on 7/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
